ALK-positive Non-small Cell Lung Cancer
8
3
4
1
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
25.0%
2 terminated out of 8 trials
33.3%
-53.2% vs benchmark
0%
0 trials in Phase 3/4
200%
2 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (8)
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
Patient-centered, Optimal Integration of Survivorship and Palliative Care
ALK Digital Pathology Outcome Predition, Multi Institutional, Restrospective Study
A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis
Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib
Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma
A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges